Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation and Depletion: 2015-2017

Historic Depreciation and Depletion for UroGen Pharma (URGN) over the last 3 years, with Dec 2017 value amounting to $207,000.

  • UroGen Pharma's Depreciation and Depletion fell 28.40% to $58,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $213,000, marking a year-over-year change of. This contributed to the annual value of $207,000 for FY2017, which is 2.82% down from last year.
  • As of FY2017, UroGen Pharma's Depreciation and Depletion stood at $207,000, which was down 2.82% from $213,000 recorded in FY2016.
  • In the past 5 years, UroGen Pharma's Depreciation and Depletion ranged from a high of $213,000 in FY2016 and a low of $113,000 during FY2015.
  • In the last 3 years, UroGen Pharma's Depreciation and Depletion had a median value of $207,000 in 2017 and averaged $177,667.
  • In the last 5 years, UroGen Pharma's Depreciation and Depletion soared by 88.50% in 2016 and then declined by 2.82% in 2017.
  • Over the past 3 years, UroGen Pharma's Depreciation and Depletion (Yearly) stood at $113,000 in 2015, then spiked by 88.50% to $213,000 in 2016, then fell by 2.82% to $207,000 in 2017.